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Sum_nury Sixty-four consecutive patients with locally advanced (n = 7) or metastatic breast cancer (n = 57).
were treated with a combination of laevofolinic acid 100 mg m-2 plus 5-fluorouracil 340 mg m -' i.v. on days
1-3, cyclophosphamide 600 mg m-2 i.v. on day 1 and epirubicin 90 mg m-' i.v. on day 1. Epirubicin dose was
progressively escalated by 0mg m2 per cycle up to 120 mg m2 in the absence of dose-limiting toxicities.
Granulocyte colony-stimulating factor (G-CSF) was given subcutaneously in order to prevent neutropenia.
Epirubicin dosage could be increased to 100 mg m-2 in 53 patients (87%), to 110 mg m2 in 31 patients (51%)
and to 120 mg m- in 18 cases (30%). In most patients the dose-limiting toxicity was represented by
myelosuppression. A statistically significant correlation was found between median white blood count (WBC)
or absolute neutrophil count (ANC) nadir and epirubicin dose level (P= 0.009: P= 0.008). Moreover, a
statistically significant correlation was observed between the number of chemotherapeutic cycles, nadir ANC
and WBC and the occurrence of anaemia and thrombocytopenia of increasing severity. These data suggest the
occurrence of progressive cumulative bone marrow toxicity. Although patients who reached different
epirubicin levels showed differences in mean dose intensity, such differences were not statistically significant.
No correlation was found between the increase in dose intensity and type, rate or duration of objective
responses. In patients with metastatic breast cancer the overall response rate was 72% (95% CL 66-78%)
with a 25% complete response rate. Median duration of response was 10 and 13 months respectively for
complete and partial responses. All patients with locally advanced breast cancer had an objective response and
underwent radical mastectomy. Projected median survival of the whole series of patients with metastatic breast
cancer was 20 + months. These data demonstrate that the combination of 5-fluorouracil with laevofolinic acid,
cyclophosphamide and epirubicin is very active against metastatic breast cancer. Use of G-CSF allows
epirubicin dosage to be increased up to 120 mg m 2cycle-. but its use may be linked to the occurrence of
sometimes severe cumulative haematological toxicity.
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Despite considerable progress achieved in the last two
decades in clinical oncology, metastatic breast carcinoma
(MBC) still remains a fatal illness. Results of palliative
polychemotherapy for MBC are still considered largely
unsatisfactory 'Henderson, 1987), but their translation to an
adjuvant setting has led to important advances in the treat-
ment of earlier stages (Henderson et al., 1988).
Doxorubicin is commonly considered as the most active
chemotherapeutic drug for the treatment of MBC, being able
to induce a nearly 40% overall response rate when employed
as a single agent (Hoogstraten, 1975). The doxorubicin 4'-
epimer epirubicin (EPI) has a more favourable therapeutic
index than doxorubicin, since at equimolar doses it shows
identical clinical activity with less haematological and cardiac
toxicity (French Epirubicin Study Group, 1988; Bonadonna
et al., 1993).
Several data from precinical studies have shown that
anthracycline drugs display a steep dose-response curve
(Razak et al., 1972; Frei and Cannellos, 1980). Clinical
studies on acute myeloid leukaemia and bone sarcomas have
shown that higher doses of anthracyclines are associated with
higher complete response rates and improved survival (Cortes
et al., 1978; Yates et al., 1982). Moreover, retrospective
analyses of clinical trials employing the cyclophosphamide,
methotrexate and 5-fluorouracil (CMF) or 5-fluorouracil,
doxorubicin and cyclophosphamide (FAC) regimens in MBC
carried out independently by Hryniuk (1987) and Tannock et
al. (1988) showed that an increased dose intensity is
associated with a better response rate and an increased
quality of life. These data have been partially confirmed, at
least in terms of response rates, in several clinical investiga-
tions on MBC treated with EPI (Hortobagyi, 1990; French
Epirubicin Study Group, 1991; Habeshaw et al., 1991; Mars-
chner et al., 1994). For these reasons new regimens contain-
ing high-dose EPI have been developed with the aim of
improving clinical results with acceptable toxicity (Hor-
tobagyi, 1990; Ferguson et al., 1993; Marschner et al., 1994).
The combination of 5-fluorouracil (5-FU). cyclophos-
phamide (CTX) and EPI employed in a wide dose range. the
so-called' FEC regimen, has been largely employed in the
treatment of MBC (French Epirubicin Study Group, 1988,
1991; Italian Multicenter Breast Study with Epirubicin,
1988). Hortobagyi (1990) recently reported substantial
differences in response rates with the FEC regimen depending
on programmed EPI dosage: the FEC regimen with EPI at a
dosage of 100 mg m-2 cycle-' obtained a 79% overall res-
ponse rate as compared with the 46% rate achieved with the
same regimen with EPI at 50mgm-2cycle-'.
The therapeutic activity of 5-FU against gastrointestinal
malignancies may be significantly enhanced by increasing the
intracellular pool of laevofolates (l-FA), which is clinically
achieved by administering variable amounts of exogenous
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I-FA to cancer patients (Allegra. 1991). The combination of
l-FA and 5-FU has also been tested in MBC patients, achiev-
ing response rates ranging from 17% to 48%, largely depen-
ding on the extent of pretreatment (Loprinnzi, 1989). With the
aim of improving clinical results some authors have tested a
modification of the FAC or FEC regimens employing 5-FU
modulated by l-FA with interesting results (Zaniboni et al.,
1989; Palmenr et al., 1991: Parnes et al.. 1991; Gebbia et al..
1992).
It has recently been reported that human recombinant
granulocyte colony-stimulating factor (G-CSF) used sub-
cutaneously is able to reduce the duration of severe
leucopenia and the incidence of mucositis and febrile events
commonly associated with intensive chemotherapy (Bron-
chud et al., 1989; Gebbia et al., 1993). G-CSF allowed a
timely readministration or even anticipation of subsequent
cycles obtained an increase in dose intensity.
According to the above-reported rationale. we carried
out a multicentre study with the combination of CTX.
5-FU/I-FA, and escalating doses of EPI with G-CSF support
with the aims of increasing anthracycline dosage to a level at
which dose-limiting toxicity could be identified, shortening
the inter-cycle interval, and improving dose intensity, as well




Since the aims of this study included both the identification
of dose-limiting toxicity and the evaluation of clinical efficacy
in terms of objective regression rate, response duration and
patient survival, measurable disease out with radiotherapy
fields according to the WHO criteria (Miller et al., 1981) was
a necessary elegibility criterion. Before entry into the study
all patients also had to fulfil the following eligibility criteria:
written informed consent as required by the ethical commit-
tee of our institutions; histological diagnosis of advanced
breast carcinoma; age> 18 and .65 years; Karnofsky per-
formance status ) 60; life expectancy ) 3 months; adequate
bone marrow function [WBC >4000 cells g1 1, platelets
(PTL)> 120000 cells g-l'. haemoglobin (Hb)> I0 gdl-'; serum
bilirubin .1.2mgdl-'. serum transaminases<twice the
normal value; serum creatinine .11.2 mg dl-1' blood urea
nitrogen (BUN) .50mgdl-'l; normal cardiac function as
evaluated by ECG and echocardiography; no signs or symp-
toms of brain metastases; absence of severe uncontrolled
cardiovascular, metabolic, neurological, respiratory, liver or
renal disease; absence of a second malignancy except for in
situ carcinoma of the cervix or cutaneous basalioma; geo-
graphical accessibiity in order to guarantee a correct follow-
up.
Previous adjuvant chemotherapy without anthracycine or
anthrachinonic drugs was permitted, but chemotherapeutic
treatment had to be withdrawn at least 12 months before
entry into the study. Previous hormonal therapies were also
permitted but they had to be discontinued at least 4 weeks
before entry.
Staging
Pretreatment staging procedures included: history and
physical examination. haemocromocytometric parameters,
routine serum chemistry tests. ECG, echocardiography and,
or radionuclide gated scan with evaluation of the left ventri-
cular ejection fraction (LVEF), chest radiograph, abdominal
sonograms, and technetium-99 bone scan. Computerised
tomography (CT) scan of the involved areas was also
required for a better definition of disease extension and
evaluation of objective response. CT scan was performed
before chemotherapy, after the first three cycles, and then
every two or three cycles in responding patients. ECG and
evaluation of LVEF were performed every cycle and every
other cycle respectively to monitor cardiac function closely.
Treatment plan and toxicity
The treatment schedule was: I-FA 100 mg m as intravenous
bolus plus 5-FU 340 mg m-2 i.v. over 15 min on days I -> 3;
CTX 600 mg m- as intravenous bolus on day 1: and EPI
90 mg m-2 i.v. bolus on day 1. G-CSF 5 jig kg- day-' was
given subcutaneously for 12 days starting from day 5 of each
cycle.
Toxicity was recorded according to the WHO criteria
(Miller et al.. 1981). In each patient EPI dosage was ten-
tatively escalated by 10mgm-' cycle-' until unacceptable
dose-limiting toxicity (DLT) ensued or the maximal dose of
120 mg m- 2 was reached. Interim blood cell counts were
performed starting from day 12 of each cycle in order to
increase EPI dosage by one dose level in the subsequent
cycle. Blood cell counts were repeated every 2 days to estab-
lish the duration of myelosuppression.
The dose-limiting toxicity was represented by any of the
following side-effects: nadir WBC < 1000 cells .l1-' with
ANC <500 cells j1-' (WHO grade 4) for > 5 days.
PTL <75 000 cells;1-' (>grade 2). precycle anaemia>
grade 2, mucositis or other extrahaematological toxicity
>grade 3. or toxicity-related delay> 8 days. If one or more
of the above mentioned side-effects occurred at any dose
level. EPI dosage was not further increased and reduced by
one dose level in the subsequent cycle.
As soon as the WBC and PTL reached acceptable values
after the nadir the subsequent cycle of chemotherapy was
tentatively given before day 21 with the aim of shortening the
inter-cycle interval. If at planned recycling (day 21) per-
sistence of mucositis, leucopenia (WBC<4000cells g-1)
and&or thrombocytopenia (PTL .120000cellsi1-') treat-
ment was delayed until day 28. With the exception of
alopecia and leucopenia. the occurrence of grade 4 toxicity of
any kind led to patients' withdrawal from chemotherapy.
Treatment was stopped if LVEF decreased by > 15% from
basal level and or patients developed initial signs of cardiac
failure. Once EPI level was defined. the dose level was main-
tained for the remainder of the trial.
The first response evaluation was performed after the third
cycle: in the case of complete objective tumour regression or
stabilisation patients received a total of six cycles; in the case
of progressive disease patients were withdrawn and followed
up. In the case of partial response patients were treated for
up to eight cycles and then followed up.
Responses and toxicity
Patients were evaluated for objective response after three
cycles according to the WHO response critenra (Miller et al.,
1981). Briefly, complete response (CR) was defined as the
complete disappearance of all signs and symptoms of tumour
for a minimum of 4 weeks; partial response (PR) was defined
as a >50% reduction in the sum of the largest perpendicular
diameters of all measurable lesions for at least 4 weeks
without a simultaneous increase in the size of any lesion or
the appearance of any new metastases; stable disease (SD) as
a .50% decrease or .25% increase in the size of tumoral
deposits; and progressive disease (PD) as a >25% increase
in the size of tumour lesions and&or the appearance of any
new metastases. For bone lesions a CR was defined as the
complete disappearance of all lesions on radiography or scan
for at least 4 weeks; PR was defined as a partial decrease in
the size of lytic lesions, recalcification of lytic lesions or
decreased density of blastic lesions (Miller et al.. 1981).
Duration of objective responses was calculated starting from
the first day of treatment until progressive disease was
recorded. Survival was calculated from the first day of
chemotherapy until death or was censored on the date of the
last follow-up.
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At entry all patients were communicated to the co-ordinating
centre and all data were centrally monitored at the
Oncological Institute of Bari. Objective tumour regressions
were reported as relative rates with 95% confidence limits
(95% CL). Univariate analysis of survival data according to
the product limit (Kaplan-Meier) estimate was carried out.
Comparison in survival distribution was made using the log-
rank test. Calculation of dose intensity was carried out ac-
cording to Hryniuk (1987) and the Wilcoxon rank sum test
was used to evaluate the differences in EPI dose intensity.
Resuts
Patient population
The main clinical and demographic characteristics ofenrolled
patients are depicted in Table I. Briefly, between April 1992
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and September 1993 64 consecutive patients with metastatic
breast carcinoma (MBC, n = 57) or locally advanced
inoperable breast cancer (LABC, n = 7) entered this study.
Median age was 50 years, and median performance status
according to the Karnofsky index was 80. Twenty-eight
patients were premenopausal (44%), and 36 (56%) post-
menopausal. Hormonal receptors were positive in 17
patients, negative in 16 and unknown in 31 cases. There were
45 ductal infiltrating carcinomas, ten lobular infiltrating car-
cinomas, and nine other histological types. Among patients
with MBC the median disease-free interval from surgical
operation to first recurrence was 3.2 years (range 1.2-5.4).
Among the 57 patients with MBC, visceral metastases
represented the dominant site of disease in 32 patients (56%)
and 45 patients (89%) presented more than one site of
disease. Sites of disease included: nodes (40 patients), bone
(23 patients), breast (15 patients), liver (16 patients), lung (13
patients), skin (five patients), pleura (four patients), and
pleural effusion (six patients). Pretreatments included: surgery
in all cases; adjuvant chemotherapy without anthracyclines in
23 patients (40%); and hormonotherapy in 19 (33%). No
patient had received chemotherapy for metastatic disease.
Dose escalation and toxicity
Sixty-one patients were evaluable for toxicity since three
patients were lost to follow-up soon after the first cycle.
Overall, a total of 384 cycles (6.3 cycles per patient) were
administered. No chemotherapy-related deaths were re-
corded.
As shown in Table H, it was possible to increase EPI
dosage from the starting dose of 90 mg mI-2 given at the first
cycle to the first step of lOOmgM-2 in 53 patients (87%).
EPI dosage could not be increased because of prolonged
grade 4 leucopenia with neutropenia in four patients, and
because of >grade 2 thrombocytopenia in four other
patients. Subsequently, EPI dosage was further increased to
llOmgm-2 in 31 patients (51%), while it was left unchanged
(100 mgm-2) or reduced (90 mggm-) in 22 patients because
of the occurrrence of grade 4 leucopenia, >grade 2 throm-
bocytopenia, >grade 2 anaemia, grade 3 stomatitis or a
combination of these toxicities. Eighteen patients (30%)
reached the final step of 120 mgm-2. In 13 patients EPI was
not increased to 120mgM-2 because of grade 4 leucopenia
(three patients), thrombocytopenia >grade 2 (three patients),
or prolonged grade 3 stomatitis (two patients). Dose escala-
tion of EPI up to 120 mgm-2 was also not achievable in four
patients who dropped out of the study because ofprogressive
cancer. The differences between median WBC and ANC
counts recorded at the four different levels of EPI were
statistically significant (P = 0.006; P=0.005 respectively).
Moreover, a clear correlation was found between EPI dose
Table II Toxicity according to EPI dosage
Dose-limiting
EPI Median number ofcells mm at nadir toxicityb
level PTL Median No. ofpatients
(mgm-2) No. ofpatients WBC ANC (n x 10) Hbg%' Cause affected
90 61 (100%) 2557 1240 160 11.5 Leucopenia 4
mrL 4




110 31 (51%) 1840 750 106 9.7 Leucopenia 5
PTL 2
Mucxsitis 2c
120 18 (30%) 1350 650 84 9.0 Leucopenia 14
PTL 4
Anaemia 3
'Hb values reported in the Table are not thoserecorded at nadirbutmedianvalues recordedjustbeforethe nextcycle of
chemotherapy. sThese data refer to those patients in whom EPI dosage could not be increased because ofunacceptable
toxicity; the highest grade toxicity per patient was reported as dose-limiting toxicity. cEs1ation of EPI dosage to
120 mg m-2 was not achievable in a further four patients because they were off-study owing to progressive disease.F-4Wmod c. i
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level and median nadir counts (WBC: r=-0.991, P= 0.009,
ANC r = - 0.%91, P<0.008). Fourteen patients required
hospitalisation and i.v. antibiotics during treatment due to
severe febrile kucopenia.
Myelosuppression was by far the most frequent side-effect
sin all patients experiecd leucopenia and/or throm-
bocytopenia and/or anaemia of some grade. Moreover,
myelosuppression represented the DLT of EPI in combina-
tion with CIX and 5-FU/l-FA in the vast majority of
patients with the exception of three patients who showed
severe extrahaematological side-effects (stomatitis). Anaemia,
as recorded before any cycle of chemotherapy, was recorded
in 46 patients (75%), six of whom had grade 3 (10%) and
two (4%) grade 4. Thrombocytopenia was observed in 34
patients (58%), of whom 13 had grade 3 and three grade 4.
Overall, nine patients required RBC transfusion due to
anaemia, and three platelet transfusion.
Figure 1 shows the median values of WBC and ANC
before startng chemotherapy, at nadir and before any cycle.
No correlation was found between the median WBC and
ANC counts at nadir and the number of chemotherapeutic
cycles. On the other hand, a statilly signifint correla-
tion was found between the number of chemotherapy cycles
and median values ofWBC (r = - 0.824, P = 0.012) or ANC
(r = 0.842, P = 0.009) recorded before any cyce of
chemotherapy. No statistical difference was found between
median nadir WBC or ANC value reoorded at any cycle. On
the other hand, the WBC curve showed a signiicant
(P=0.002) decrease in median WBC levels after cyde 5
which may suggest the occurrence of cumulative toxicty
and/or a mild reduction of marrow protection despite the use
of G-CSF.
Figure 2 shows PTL and Hb values plotted against number
of cycles of chemotherapy. Analysis of Hb lels shows a
markable progressive toxicity with a median reduction of
Hb value of 2.7 gdl-' between preteatment and final values
(P<0.005). A signifint statistical correlation was found
between number of cycle and development of anaenia
(r = - 0.938, P = 0.0001). Such an effect was less evident for
PTL valus which showed decrease at nadir with a rapid
return to starting values and no staically signifiant
differences between prettment and final values. However,
analysis ofnadir FiL values showed a statically signifiant
correlation between thrombocytopenia and the number of
chemothwapeutic cycles (r = -0.709, P = 0.049). Ineas in
the frequency of cycle administration was possible in 20
patients which showed shorteing of the progammed inter-
cycle interval to a median of 18 days (range 16-20). In most
cases this was possible during the first three cyces after
which cumulative bone marrow toxicity hampered shortening
of the inter-cycle interval.
The median cumulative dosage of EPI was 645 mgm-2 per
patint with a median dose intensity of 38.41 mgm-2 week-'
which represented a 28% incrase over the starting dosage.
In the group of patients who could not receive EPI over
90mgm-2 the mean dow intensity was 33.38 mg m-2 week-',
in the goup of patients who reached 100mg m-2 the mean
dose intensity was 35.78MgM-2 week-', while for those who
reached 110 and 120 mg m-2 the mean dose intensity of EPI
was 36.19 mgM-2 wMee-' and 40.47 mgM-2weelk' respec-
tively. Thee differences in mean dose intensity were not
statisly signifant. No correlation was found between
EPI dose lvels and type or rate of objective response.
AM patients experienced grade 3 alopeca. Gastrointestinal
toxicity was rather mild. Grade 1-2 nausea/vomiting and
stomatitis were recorded in 33 (54%) and 24 (39%) patients
repecively, while grade 3 vomiting and stomatitis were
recorded in 12 (20%) and five (8%) patients respectively.
Diarrhoea was mild with only one case of grade 3. With
rgrd to cardiotoxicity, one patient developed a myocardial
infarction after seven cycks of a cumulative EPI dosage of
700 mg m2 and died 13 months after the begnning of
chemotherapy of progressive cancer. In one other patient
chemotherapy was stopped because of a 25% fall in LVEF
after seven cycles at a cumulative EPI dosage of 760 mg m-2.
In a further three patients a 10% reduction in LVEF was
noted but it did not fall below the normal nimts: none of
these patients developed any clinical sign of heart failure.
Objective responses andsurvival
Overall, 61 out of 64 enrolled patients were evaluable for
response. Three patients were lost to follow-up after the first
cycle of chemotherapy before response evaluation. These
patients were considered as treatment failures and thus res-
ponse rates were calated according to an intent to treat
anabsis considering all enroled patients (n = 64).
Among the 57 patints with metastatic disease there were
14 CR (25%) and 27 PR (47%) with an overall response rate
(ORR) of 72% (95% CL 66-78%), while nine patients
(16%) had stable disease, and four (7%) prog (three
lost to follow-up). The median duration of CR and PR was
10 months and 13 months respectively. On the other hand,
all seven patients with inoperable LABC achieved a PR and
underwent radical mastectomy. All but one of these patients
are alive and four are still dis free 18, 21, 31 and 32
months after surgery.
Analysis of response according to the site of metasases is
shown in Table m. Soft tissue tumoral deposits (breast, scin
and lymph nodes) as well as pleurl effusions showed the
highest response rates. No differences were seen between
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showed an objective response. Bone metastases responded in
65% of cases, but response rate at soft tissue metastases was
higher than that recorded at bone lesions (87% vs 65%,
P<0.05). Table IV shows analysis ofresonse rates accord-
ing to the dominant site of disease. As expected, patients
with inoperable LABC showed the highest response rate, but
not complete responses. Response rates did not vary
signifiantly between the other groups. There was a difference
in response rates between MBC patients with 1-2 sites of
disease (81% ORR) and those with 3-4 sites (57% ORR),
but the difference did not reach statistical significnce.
Among the 57 MBC patients who had previous adjuvant
chemotherapy, 14 had a major response (CR + PR) for an
overall response rate (61%); among the 34 patients who had
not had adjuvant chemotherapy, 27 had a major response
(79%). This difference was not statistically signiiant.
Among patients with MBC in whom sites of progressive
dises were recorded, 43% relapsd in their on-study organ
site of disease, 40% in previously disease-free organs and
17% in both sites. Progression of disease occurred in single
or in multiple sites in 31 (65%) and 17 (35%) patients
respively, with a higher incidence of bone metastases
(42%) followed by metastatic disease to the brain (19%).
After a median follow-up of 18 months (range 7-33
months) projected median survival of MBC patients was
20+ months. Among responding patients (CR + PR) there
was a statisially signnt difference in survival in favour
of patients with bone-dominant site of disease as compared
with those with visceral and soft tissue sites (P = 0.03).
Dbisc"-im
In the last 15 years the results of systemic treatment for
advanced breast cancer have reached a plateau. Several
efforts have been made to improve clinical results by increas-
ing the dose intensty of chemotherapeutic treatments
(Henderson et al., 1988; Tannock et al., 1988; Hortobagyi,
1990; Marschner et al., 1994). In fact, haematopoietic growth
factors have been employed as rescue from myelosuppression
with the aims of increasing the dose of antineoplastic drugs
and also shortening the inter-cycle interval (Bronchud et al.,
1989; O'Shaughness et al., 1990; Piccart, 1990; Ten Bokkel
Huinink and Clavel, 1990; Habeshaw et al., 1991; Hoekman
et al., 1991; Gebbia et al., 1994).
The aims of this study were to evaluate the possibility of
increasing EPI dosage over 90 mgm-2cycle-', to identify the
dose-limiting toxicity of EPI in combination with CIX and
Table m Objective response according to single site ofdisea
No. of Type ofresponse
Site patis CR PR SD PD CR + PR(%)
Viscra
Lung 13 5 5 3 - 10 (77)
Liver 16 6 6 2 2 12 (75)
Pleura 4 3 - - 3 (75)
Phural
Effion 6 4 2 - - 6 (100)
Bone 23 2 13 8 - 15 (65)
Soft tissue
Breast 22 5 15 1 1 20 (91)
Lymph nodes 40 20 13 5 2 33 (82)
Skin 5 4 1 - - 5 (100)
Table IV Response according to dominant site ofdisease
No. of Type ofresponse
Site paints CR PR SD PD CR+ PR (%)
Vilscera 32 11 13 5 3 24(75)
Bone 14 - 11 3 - 11 (79)
Soft tissue 8 3 3 1 1 6 (75)
LABC 7 - 7 - - 7 (100)
5-FU/1-FA, employing a fixed dose of G-CSF and to test the
clinical activity of such a regimen in advanced breast cancer.
In this series of 61 patients the use of subcutaneous G-CSF
allowed us to increase EPI by lOmgm-2 cycle-' above the
starting dose level of 90 mg m-2 cycle-' in 53 patients (87%),
by 20mgm 2 in 31 patients (51°%) and by 30mgm 2 in 18
cases (30%). An increase in frequency of administration was
not possible in all patients in most instances because of
myelotoxicity and mucositis. However, shortening of inter-
cycle interval was possible in 20 patients but only for a few
cycles because of cumulative toxicity. These data confirm,
although only partially, the data reported by other authors,
who were able to reduce the inter-cycle interval in a series of
patients with MBC treated with high dose EPI + CTX (Pic-
cart, 1990). It should be stressed that the chemotherapy
regimen employed in the latter study was different from that
given in our study.
In most patients the dose-limiting toxicity of high-dose EPI
in combination with CTX and 3 day 5-FU/l-FA was
myelotoxicity, even though three patients did not complete
dose escalation because of mucosal toxicity. Analysis of
haematological parameters showed a progressive decrease in
median haemoglobin values, which was statistically cor-
related to the number of chemotherapeutic cycles. In fact, a
median 2.7 g% loss of haemoglobin was recorded between
basal and off-therapy values. A similar, but less marked,
progressive increase in the severity of thrombocytopenia at
nadir was also noted as the number of cycles increased.
Moreover, although G-CSF rescue was possible in all cycles
since differences in nadir WBC and ANC levels were not
statistically significant, however G-CSF-induced spikes in
ANC recorded before any cycle were progressively less
marked as the number of chemotherapeutic cycles increased.
These data suggest that sequential cycles of intensive
chemotherapy with G-CSF marrow rescue may result in a
cumulative myelosuppression which was evident as an unex-
pected high rate of significative anaemia, and in throm-
bocytopenia and leucopenia of increasng severity. This
observation has been reported also by other authors (Hoek-
man et al., 1991) employing granulocyte-macrophage
colony-stimulating factor (GM-CSF) as rescue from myelo-
suppression induced by high-dose doxorubicin plus cyclo-
phosphamide.
Although patients treated with EPI 120 mg m-2 achieved a
better dose intensity than patients treated at lower dose
levels, these differences in dose intensity were not statistically
significant and no correlation was found between EPI dose
or dose intensity levels and type or rate of objective res-
ponses.
The ORR achieved in this multicentre study was 72%
(95% CL 66-78%) with a 25% complete response rate. The
median durations of complete and partial responses were 10
and 13 months respectively. The above-reported data confirm
that this combination is active against MBC, achieving a
high overall response rate similar to that reported with
similar regimens (Hortobagyi, 1990; O'Shaughnessy et al.,
1990). Comparison of these results with those achieved by
authors employing the same regimen with a lower dose of
EPI, shows that higher doses of EPI may induce a 15%
increase in ORR but a doubling in complete response rate
(Palmeri et al., 1991). However, it should be stressed that
whether higher doses of EPI are associated with an increase
in both rate and duration ofobjective response is beyond the
aims of this study, and that this issue can be settled only in
prospective randomised trials.
In conclusion, the DLT of EPI in combination with CTX
and 3 day 5-FU/l-FA is represented by myelosuppression.
These results further confirm that the use of G-CSF, given by
a subcutaneous route, is effective in permitting an icreased
EPI dosage in such a combination regimen above the con-
ventional dose, up to 120mgm-2cycle-' in a significant
percentage of patients. Intensive chemotherapy with G-CSF
support may however sometimes result in very severe
cumulative toxicity, which in the present study was
represented by progressive anaemia and a trend towards
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increasing thrombocytopenia. We feel that EPI 110mgm2
with G-CSF support can be employed in combination with
CTX and 5-FU l-FA on an outpatient basis, but with a close
follow-up. The combination of CTX. 5-FU/u-FA and high-
dose EPI with G-CSF support is highly effective against
advanced breast cancer. However, this regimen cannot be
recommended as routine standard therapy for metastatic
breast cancer due to its significant toxicity and high cost,
unless very aggressive and intensive chemotherapy is necs-
sary.
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